C12N 2710/16642
Virus or viral particle as vehicle
Official title: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N2710/16642 (Virus or viral particle as vehicle) appears on 5 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 9
- Assignees
- 8
- Inventors
- 23
- Latest grant
- 16 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 2 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 1 | 2 |
| 2019 | 0 | 0 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
By publication year.
Recent patents
- Split-immunotoxins for boosting oncolytic virus toxicity16 Jul 2024US 12,037,370 B2Ohio State Innovation Foundation
- Oncolytic virus therapy for resistant tumors28 Apr 2020US 10,633,636 B2The General Hospital Corporation
- Oncolytic virus therapy for resistant tumors9 Jan 2018US 9,862,932 B2The General Hospital Corporation
- Methods for sustained and regulatable gene expression using viral based expression vectors2 May 2017US 9,636,354 B2University of Florida Research Foundation, Inc.
- Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression5 May 2015US 9,023,617 B2University of Florida Research Foundation, Inc.
- Pharmaceutical compositions, kits and methods for treating tumors3 Nov 2022US 2022/0347243 A1Immvira Co., Limited
- Viral-vectored vaccine for malaria21 Oct 2021US 2021/0324416 A1
- Split-immunotoxins for boosting oncolytic virus toxicity31 Dec 2020US 2020/0407405 A1Ohio State Innovation Foundation
- Dna launched rna replicon system (drep) and uses thereof10 Sep 2020US 2020/0283796 A1Massachusetts Institute of Technology
- Oncolytic virus therapy for resistant tumors31 May 2018US 2018/0148694 A1The General Hospital Corporation
Most cited
By later US patents
- Oncolytic virus therapy for resistant tumors4US 9,862,932 B2The General Hospital Corporation · 2018
- Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression1US 9,023,617 B2University of Florida Research Foundation, Inc. · 2015
- Methods for sustained and regulatable gene expression using viral based expression vectors1US 9,636,354 B2University of Florida Research Foundation, Inc. · 2017